Mediaboss Marketing

Host Gator Word Press Setup
Step by Step Word Press setup on Host Gator.

By: Plus Pursuit

Read this article:
Host Gator Word Press Setup - Video

DGAP-News: Bastei Lbbe AG / Key word(s): Miscellaneous Bastei Lbbe AG: Creditreform upgrades rating from BBB to BBB+

18.12.2013 / 13:34

=--------------------------------------------------------------------

Bastei Lbbe AG, which has been quoted on the Prime Standard of the Frankfurt Stock Exchange since 8th October 2013, has been reclassified by Creditreform Rating AG as Investment Grade BBB+. Until now, the credit rating of the Cologne based publisher had only been rated with the lower BBB grade. This improved rating reflects the publisher's successful development in recent years. Creditreform justified the upgrade on the basis that the forecasts for the 2013/2014 financial year had improved significantly on budget and previous year's values. Furthermore, the IPO boosted the equity ratio significantly and improved liquidity long term.

In November Bastei Lbbe AG published its half-year figures to 30th September 2013. Compared to the same period in the previous year, sales between 1st April 2013 and 30th September 2013 improved by 37.8% to EUR56.0 million (PY: EUR40.6 million). EBIT increased disproportionately by 232% to EUR7.5 million (PY: EUR2.3 million). 'Overall our technical analysis demonstrated an improvement in the key financials for the coming year-end figures. We believe Bastei Lbbe AG is in a stronger position and consider its structure and content to be sufficient enough to be able to generate further growth in the future,' according to the latest Creditreform assessment.

Thomas Schierack, Chairman of the Board of Directors of Bastei Lbbe AG, comments: 'The rating upgrade by Creditreform is further evidence of our solid business policy. We are pleased to be able to justify the confidence of our investors. We will therefore continue to consistently work on driving forward the dynamic development of Bastei Lbbe AG.'

Christmas trade is once again performing well. Bastei Lbbe is currently celebrating the big success of Jeff Kinney's eighth novel in the Diary of Wimpy Kid series, 'Hard Luck'. Since it was published on 21st November 2013 there have already been more than 1 million copies distributed.

Bastei Lbbe is one of this year's most successful non-fiction publishers. In 2013 it scored a total of 13 titles on the non-fiction bestseller list (Media Control, Focus).

End of Corporate News

=--------------------------------------------------------------------

Go here to read the rest:
PRESS RELEASE: Bastei Lübbe AG: Creditreform upgrades rating from BBB to BBB+

PRESS RELEASE: Nanogate AG: Inkjet project launched for a large Swedish automobile manufacturer

NANOGATE AG / Key word(s): Miscellaneous

18.12.2013 11:00

Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer / publisher is solely responsible for the content of this announcement.

=--------------------------------------------------------------------------

Nanogate AG: Inkjet project launched for a large Swedish automobile manufacturer

Sicralan inkjet coating enhances gear lever plaque with a multifunctional, scratchproof high-performance surface

Gttelborn, Germany, 18 December 2013. Nanogate AG (ISIN DE000A0JKHC9), a leading international integrated systems provider for high-performance surfaces to fulfil another large order thanks to its unique inkjet technology. The multi-year order represents an annual sales volume in the six-figure euro range.

The project involves enhancing gear lever plaques with a transparent, multifunctional coating of the Sicralan brand. At its location in Schwbisch Gmnd in Germany, the subsidiary GfO has begun production to protect the components for a new range of vehicles by a Swedish car manufacturer. These components are subject to considerable wear and tear and will be protected against scratches and external influences. The vehicles will thus receive an additional enhancement regarding the quality and durability of the installed components.

GfO's inkjet technology makes it possible in particular to partially coat small, two-dimensional components without requiring a mask. The technology makes it possible to handle large numbers of components efficiently, to above-average quality standards and at a brisk pace. Ralf Zastrau, CEO of Nanogate AG, said: 'With this order, we have been able to further increase our scope of deliveries to Scandinavia, a part of our increasingly international alignment. We intend to continue on this path and build on this in the coming years.'

More:
PRESS RELEASE: Nanogate AG: Inkjet project launched for a large Swedish automobile manufacturer

DGAP-News: Evotec AG / Key word(s): Alliance Evotec and Yale University to collaborate on cancer therapy

17.12.2013 / 07:30

=--------------------------------------------------------------------

* First collaboration within open innovation alliance with Yale University * Collaborative effort will explore novel mechanisms, targets and compounds that have the potential to interfere with DNA repair to identify new targets for drug discovery and development

Hamburg, Germany - 17 December 2013: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and compounds that have the potential to interfere with DNA repair. DNA repair mechanisms allow cancer cells to cope with extensive genome rearrangements as well as to escape conventional radio- and chemotherapy and thus have potential applications in many cancer indications. This is the first collaboration to be announced as part of Evotec's open innovation alliance with Yale University.

TargetDBR is based on systematic cell screens designed to identify DNA repair inhibitors and their mechanisms of action. The application of Evotec's high-content cellular screening platforms allied to chemoproteomics-based target deconvolution will enable the identification not only of novel DNA repair inhibitors but also of novel tractable targets in DNA repair pathways. The initial focus will be on increasing the effectiveness of glioblastoma brain tumour treatments but it is expected that the DNA repair inhibitors will also find application in many other cancer types. Yale and Evotec will collaborate in a highly integrated fashion and share potential commercial rewards.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'Deficiencies in DNA repair mechanisms constitute not only initiating events leading to cancer but also provide potential therapeutic targets on the basis of the concept of synthetic lethality. We are very excited about the opportunity to collaborate with Peter and Ranjit to identify and develop novel classes of DNA repair inhibitors that have the potential to become highly effective therapeutics against difficult to treat cancers such as glioblastoma.'

'Through this collaboration with Evotec, novel biological discoveries and medical insights made at Yale are being effectively translated into a state-of-the-art drug discovery project. The collaboration is already demonstrating the benefit of the Yale Evotec open innovation alliance in accelerating drug discovery projects', said Dr Jon Soderstrom, Managing Director of Yale's Office of Cooperative Research.

Financial details were not disclosed.

ABOUT THE EVOTEC AND YALE OPEN INNOVATION ALLIANCE In January 2013, Evotec AG and Yale University entered into a strategic partnership. Under the agreement, Evotec and Yale are leveraging first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec's drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.

Continue reading here:
PRESS RELEASE: Evotec and Yale University to collaborate on cancer therapy

PRESS RELEASE: First Sensor AG: First Sensor Optimizes Financial Flexibility for Growth Strategy

DGAP-News: First Sensor AG / Key word(s): Miscellaneous First Sensor AG: First Sensor Optimizes Financial Flexibility for Growth Strategy

17.12.2013 / 17:16

=--------------------------------------------------------------------

Press release

First Sensor AG Peter-Behrens-Str. 15 12459 Berlin, Germany

First Sensor's Shares: ISIN DE0007201907 ? WKN (German Securities Identification Number) 720190

First Sensor Optimizes Financial Flexibility for Growth Strategy

Berlin, December 17, 2013 - First Sensor, the leading provider of high-quality, customer-specific sensor solutions, is securing and optimizing its financial position ahead of the implementation of the planned growth strategy. On December 17, 2013, the stock company successfully placed promissory note loans totaling EUR31.0 million. The promissory note loans replace the syndicated loan of around EUR29 million, which had been in place since 2011, in full.

For First Sensor AG, the negotiations with financing partners prioritized the greatest possible business freedom and greater term security. The conversion of the existing syndicated loan into promissory note loans offers the Group an array of advantages:

Read more from the original source:
PRESS RELEASE: First Sensor AG: First Sensor Optimizes Financial Flexibility for Growth Strategy